Veterinary sedative in fentanyl tied to severe withdrawal

Clinical takeaway: Suspect medetomidine exposure in patients using illicit fentanyl when withdrawal turns unexpectedly severe, particularly when hypotension and bradycardia flip to hypertension and tachycardia. Consider alpha-2 agonists alongside methadone and buprenorphine. 

People abusing fentanyl usually have few ways to know what else they are taking, and the list of potentially included substances keeps changing. Medetomidine, a veterinary alpha-2 agonist sedative, moved into the US drug supply fast enough to prompt a CDC health advisory in April. Provisional CDC data show the drug concentrated in the Northeast and spreading unevenly westward. 

Medetomidine exposure brings profound sedation, bradycardia, and hypotension, and abrupt cessation after repeated exposure is associated with a potentially life-threatening withdrawal syndrome distinct from opioid and opioid-xylazine withdrawal. The clinical outlines so far come from emergency medicine and CDC surveillance, leaving out the patient's side: how exposure feels, how withdrawal unfolds, and what it does to treatment. A University of Pittsburgh interview study of hospitalized adults supplies that account. 

Interviews surfaced four themes: helplessness to control the drug supply, vulnerability from the drug's effects, severe withdrawal, and ineffectiveness of standard medications against it. Participants described exposure as unwanted and unavoidable, with adulterants changing faster than they could track. The sedation itself created danger beyond overdose: losing consciousness in public left people open to robbery, assault, and injuries from prolonged immobility, and several described new fears of using without someone familiar nearby. 

Withdrawal drove many to hospital care they had never needed before, with intractable vomiting and symptoms they could not manage alone or in outpatient settings. CDC provisional data track the spread, with medetomidine in 74.2% of opioid-positive drug samples in the Northeast, 56.2% in the Midwest, 30.1% in the South, and 3.8% in the West. 

Medetomidine withdrawal begins four to six hours after last use and peaks at about 24 hours, faster and more severe than fentanyl withdrawal that starts within six to 24 hours and peaks at 48 to 72 hours. Its markers run beyond the familiar opioid picture: severe hypertension above 200/100 mm Hg, tachycardia above 150 beats per minute, rigors or myoclonic jerks, and QTc prolongation. "The methadone and suboxone does not even help or touch it because it's not an opiate," said Patient 4, a 36-year-old man, echoing others who reported the medications missed the medetomidine component. Some said the prospect of withdrawal kept them from seeking or staying in treatment at all. 

Researchers at the University of Pittsburgh interviewed 16 hospitalized adults with opioid use disorder and medetomidine exposure confirmed by urine toxicology or positive test strip results, sampled purposively between September and November 2025. Half were women, mean age was 34, 88% were White, and 31% were unhoused. Semi-structured interviews ran until thematic saturation, with transcripts coded inductively and themes set by team consensus. 

The authors' health system, UPMC, has built a withdrawal management protocol around scheduled oral alpha-2 agonists, with escalation to intravenous dexmedetomidine for patients who cannot tolerate or do not respond to an oral regimen, and the authors point to addiction medicine and toxicology consultation as further support. Naloxone guidance is clear that this treatment does not reverse medetomidine toxicity but should still be given for suspected opioid overdose with respiratory depression, titrated to restored breathing rather than consciousness. 

"The rapidly evolving drug supply continues to introduce new and clinically significant adulterants, including medetomidine," the authors conclude. "These trends underscore the need for proactive, rather than reactive, clinical systems that can anticipate and adapt to emerging substances." 

Source: Pressimone C, et al. (2026 Sep 15) Ann Intern Med. Medetomidine Exposure in a Shifting Drug Landscape: Insights From Patient Experiences